View in Browser

Sign up for Reuters newsletters

Recommended by Alessandra Galloni, Reuters Editor-in-Chief

The popularity of weight loss drugs has been one of the biggest health stories of 2023. In this fascinating story, reporters Robin Respaut and Chad Terhune talk to patients about their experience while taking drugs including Novo Nordisk’s popular Wegovy and Ozempic, which respectively are approved to treat weight loss and diabetes.

They also dig into the US Food and Drug Administration’s database to find that the FDA has received 265 reports of suicidal thoughts or behavior in patients while taking these or similar medicines since 2010. I found it an engaging and important story and hope you agree.

A big welcome to the inaugural edition of One Essential Read, which will bring you a compelling story, photo, video or graphic every day.

Dawn Heidlebaugh says she felt lethargic, depressed and sometimes suicidal after taking Ozempic. REUTERS/Megan Jelinger

Sponsors are not involved in the creation of newsletters or other Reuters news content.

Reuters One Essential Read is sent 5 days a week. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here.

Want to stop receiving this email? Unsubscribe here.
To manage which newsletters you're signed up for, click here.

Reuters Terms & Conditions and Privacy Statement